Concepedia

Author

Vincent Haddad

Institut Gustave RoussyORCID

Also Known As

V. Haddad, Vincent Haddad

50

Publications

4.4K

Citations

20

H-Index

56

Concepts

All Affiliations

Institut Gustave RoussyAmgen (United States)Amgen (United Kingdom)AstraZeneca (United Kingdom)Medical University of Vienna
VH

About

Vincent Haddad is an author at Institut Gustave Roussy specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

14

728

2

Health Sciences

4

4

218

3

Engineering

1

1

40

4

Biomedical Engineering

1

1

40

5

Cell Biology

1

1

25

Vincent Haddad

×

27

Publications

4.3K

Citations

20

H-Index

YearCitations

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

Ken A. Olaussen, Ariane Dunant, Pierre Fouret,

New England Journal of Medicine

2006

1.7K

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio,

Blood

2018

810

Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients

Sylvie Bonvalot, Hany Eldweny, Vincent Haddad,

European Journal of Surgical Oncology

2007

271

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses

Tony Mok, Sang‐We Kim, Yi‐Long Wu,

Journal of Clinical Oncology

2017

183

Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer

Karim Fizazi, Philippe Beuzeboc, J. Lumbroso,

Journal of Clinical Oncology

2009

173

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

Charles S. Fuchs, Sérgio Jobim Azevedo, Takuji Okusaka,

Annals of Oncology

2015

163

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

Monique B. Nilsson, Huiying Sun, Lixia Diao,

Science Translational Medicine

2017

147

Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non–Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program

Martin Filipits, Robert Pirker, Ariane Dunant,

Journal of Clinical Oncology

2007

116

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

Tina Cascone, Li Xu, Heather Lin,

Clinical Cancer Research

2017

84

Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non–Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program

Martin Filipits, Vincent Haddad, Katharina Schmid,

Clinical Cancer Research

2007

80

Page 1